{"id":"course-a1-vin","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Infection"}]},"_chembl":{"chemblId":"CHEMBL389471","moleculeType":"Small molecule","molecularWeight":"1110.09"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a multi-agent chemotherapy combination used in pediatric cancer treatment. Vincristine is a vinca alkaloid that binds to tubulin and prevents microtubule assembly, leading to cell cycle arrest and death. Course A1 typically refers to a standardized induction chemotherapy protocol that may include additional agents such as daunorubicin, cytarabine, and L-asparaginase, which work through complementary mechanisms including DNA intercalation and protein synthesis inhibition.","oneSentence":"Course A1 + Vin is a combination chemotherapy regimen that uses vincristine (Vin) alongside other agents in Course A1 to disrupt microtubule formation and induce apoptosis in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:07:45.160Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pediatric acute lymphoblastic leukemia (ALL)"},{"name":"Pediatric acute myeloid leukemia (AML)"}]},"trialDetails":[{"nctId":"NCT04881838","phase":"PHASE3","title":"CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2021-03-01","conditions":"Pediatric Anaplastic Large Cell Lymphoma","enrollment":172}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Course A1 + Vin","genericName":"Course A1 + Vin","companyName":"Children's Cancer Group, China","companyId":"children-s-cancer-group-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Course A1 + Vin is a combination chemotherapy regimen that uses vincristine (Vin) alongside other agents in Course A1 to disrupt microtubule formation and induce apoptosis in cancer cells. Used for Pediatric acute lymphoblastic leukemia (ALL), Pediatric acute myeloid leukemia (AML).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}